Background: As the COVID era unfolds, researchers reveal that rapid changes in viral
genetic material allow viruses to circumvent challenges triggered by the host immune …

Background & Aims: Molnupiravir is an oral antiviral drug which is used in the treatment of
patients with COVID-19. The purpose of this study was to investigate the effectiveness and …

The first case of SARS-CoV-2 infection in United States was confirmed on January 19, 2020,
in a man who had returned home to Snohomish County, Washington on January 15, 2020 …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …

Concerns have been raised about the actual benefit and safety of molnupiravir, a new
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …

Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …

On 4 November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA)
announced that it had approved molnupiravir (▼ Lagevrio) as the first oral antiviral drug …